Beyond basic characterization: the synergistic power of Tapestri and patient-derived xenografts to accelerate drug discovery

Acute myeloid leukemia (AML) stands as a significant challenge among hematological malignancies, marked by the rapid proliferation of aberrant myeloid cells. Despite the swift evolution of available treatments for AML, a definitive cure remains elusive. Over the past century, the array of techniques to study diseases has increased almost exponentially, with disease modeling emerging as a pivotal avenue. Patient-derived xenografts (PDXs) represent a groundbreaking approach that has reshaped our capacity to investigate, comprehend, and address diseases.

Leveraging the synergy of single-cell DNA sequencing and PDXs has empowered us to unveil clonal dynamics, pinpoint genetic mutations, and delve deeper into the intricate evolutionary trajectories of tumors. These insights offer a profound understanding of the molecular underpinnings of drug responses, thereby guiding the development of personalized treatment regimens for cancer patients. In this study, we demonstrate the Tapestri® Platform’s capability to elucidate clonal changes in AML PDXs post-treatment.